Chair Anne L. Fuhlbrigge, MD, MS Assistant Professor of Medicine Harvard Medical School Clinical Director, Division of Pulmonary and Critical Care Medicine Brigham and Women’s Hospital, Pulmonary Division Boston, MA
Faculty James F. Donohue, MD Professor of Medicine Division of Pulmonary and Critical Care Medicine University of North Carolina at Chapel Hill Chapel Hill, NC
Nicola A. Hanania, MD, MS Associate Professor of Medicine Pulmonary and Critical Care Medicine Director, Asthma Clinical Research Center Baylor College of Medicine Houston, TX
AMA PRA Category 1 Credit TM Medium
Chronic obstructive pulmonary disease (COPD) is a slowly progressive respiratory disease characterized by airflow limitation that is not fully reversible. Manifestations of COPD include dyspnea, poor exercise tolerance, chronic cough with or without sputum production, wheezing, and respiratory failure or right heart failure. In the United States, COPD affects more than 5% of the adult population and is the third leading cause of death. Advances in medical therapies and better disease management approaches have increased the recognition that COPD is preventable and treatable. Yet, COPD remains both underdiagnosed and undertreated in primary care settings.
. Target Audience
This activity is intended for internal medicine physicians and other primary care clinicians involved in the diagnosis and treatment of patients with COPD.
Upon completion of this educational activity, the participant should be able to:
Identify patients for whom a diagnosis of COPD should be considered.
Utilizing the GOLD guidelines, complete a combined assessment of COPD, including symptoms, spirometry, phenotyping, airflow limitation, and the risk of exacerbations.
Combine the use of pharmacologic interventions and behavioral interventions to increase smoking cessation success among patients with COPD.
Recommend nonpharmacologic interventions, including pulmonary rehabilitation, for patients with COPD to improve exercise capacity.
Provide an overview of evidence-based treatment recommendations for the use of pharmacologic therapies in the treatment of stable COPD.
Discuss the impact of comorbidities associated with COPD on therapeutic strategies.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Anne L. Fuhlbrigge, MD, MS has disclosed the following:
Consultant/Advisor: Advanced Health Media, ICON Medical/Beacon Bioscience
Research/Grant Support: NIHBI
James F. Donohue, MD has has disclosed the following:
Consultant/Advisor: Boehringer Ingelheim, Forest, GlaxoSmith Kline, Meda, Mylan, Novartis, Sunovion
Nicola A. Hanania, MD, MS has disclosed the following:
Consultant/Advisor: Boehringer Ingelheim, GlaxoSmith Kline, Mylan, Pearl Therpautics, Sunovion
Research/Grant Support: Boehringer Ingelheim, GlaxoSmith Kline, Mylan, Pearl Therpautics, Sunovion
Penn State faculty and staff involved in the development and review of this activity have nothing to disclose.
Gena Dolson, MCM Education Senior Medical Writer, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 70% or better on the post-test.
The online activity will take approximately 75 minutes to complete.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5557-15-T. Commercial Support Statements
This educational activity is supported by independent medical education grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Sunovion Pharmaceuticals, Inc.
There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.
Review the intended audience, learning objectives, and author disclosures.
Study the educational content online.
Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, Boehringer Ingelheim, or Sunovion. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.